| Trial ID: | L2743 |
| Source ID: | NCT03492580
|
| Associated Drug: |
Canagliflozin
|
| Title: |
A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2|Cardiovascular Diseases
|
| Interventions: |
DRUG: Canagliflozin|DRUG: Empagliflozin|DRUG: Dapagliflozin|DRUG: Dipeptidyl Peptidase-4 (DPP-4) Inhibitors|DRUG: Glucagon-like Peptide-1 (GLP-1) Agonist|DRUG: Anti-hyperglycemic Agents (AHA)|DRUG: Thiazolidinediones (TZD)|DRUG: Sulfonylureas (SU)|DRUG: Insulin
|
| Outcome Measures: |
Primary: Number of Hospitalizations for Heart Failure, Number of hospital admissions with a primary diagnosis of 'heart failure' will be reported., Approximately 4-years|Number of Participants with Below Knee Lower Extremity Amputation Events, Number of participants with new below-knee lower extremity amputation procedures, excluding recent (within 30 day) revisions will be reported., Approximately 4-years |
|
| Sponsor/Collaborators: |
Sponsor: Janssen Research & Development, LLC
|
| Gender: |
ALL
|
| Age: |
CHILD, ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
714582
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2018-02-22
|
| Completion Date: |
2018-06-25
|
| Results First Posted: |
|
| Last Update Posted: |
2018-08-27
|
| Locations: |
Janssen Investigative Site, Titusville, New Jersey, 08560, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT03492580
|
